



## What's Doing

Last week I caught up with Dr Bill Ketelbey who is the MD of a listed bio tech company called [Actiogen Medical \(ACW.asx\)](#).

I haven't followed the ACW story for that long, but I am interested in learning more about it as my late Grandmother unfortunately suffered from Alzheimer's & if these guys can develop a new drug that can treat the disease better than the out-dated ones that are currently being used then they could well be on to something big.

*Imagine an accessible market worth over US\$5bn in annual revenue, that is doubling in volume every 20 years, and serviced by 20 year-old generic drugs that provide marginal benefit at best.*

*That's the Alzheimer's disease market.*

*A huge and rapidly growing market and a one with a massive unmet medical*

*need.*

*There are an estimated 50m Alzheimer's sufferers globally, over 400,000 in Australia and only four registered therapies that provide around 6 months benefit. In fact, about one third of Alzheimer's patients don't respond at all to the available drugs or are unable to tolerate them. Alzheimer's disease is a persistent neurodegenerative disease that will eventually overwhelm any benefit provided by the available medications, and once a patient has failed on one drug they are unlikely to respond to any of the others.*

*The need to develop new effective therapies has never been more urgent, particularly at a time when several high-profile drug trials based on more traditional approaches to treating Alzheimer's have failed.*

*Actinogen Medical, an ASX listed biotech, that has stepped up to the challenge.*

*The company is developing Xanamem, a drug that has been specifically designed to block the production of cortisol in the brain. Persistently raised cortisol, the stress hormone, has been shown from numerous independent studies to be associated with the development and progression of Alzheimer's disease. High cortisol levels are toxic to the brain, and particularly to the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.*

*Actinogen has previously shown that inhibition of excess cortisol in the brain improves cognition, and is now conducting XanADu, a clinical trial of Xanamem in Alzheimer's patients to try and demonstrate a similar benefit in Alzheimer's disease.*

*XanADu is being conducted across 20 clinical trial sites across the USA, the UK and Australia. It's a double-blind, placebo controlled and will enrol 174 patients. As of 12<sup>th</sup> February, 72 patients have been enrolled into the trial, representing 41% of the total enrolment, and more than 30 patients have completed the study, including the 12-week treatment period and the 4-week follow-up.*

*The study is on schedule, with the final patient expected to be enrolled by Q4 this 2018.*

***Topline results from XanADu are expected by Q2 2019.***

***If Xanamem can be shown to be effective in the treatment of Alzheimer's disease, it will be the most meaningful advance in Alzheimer's treatment in decades, representing a rare and compelling investment opportunity which is what has really got me interested.***

***Actinogen could provide the breakthrough needed in the treatment of Alzheimer's disease, through the development of Xanamem.***

***The company's excellent progress with XanADu, strong patent portfolio and novel treatment approach provide a compelling opportunity for investing in the development of a promising and effective new treatment for this dreadful disease.***

***The board is also quality***

**Geoff Brooke - founder of GBS Ventures - exits of \$800m, \$240m, \$400 million - so he knows the game of exits and fingers crossed for ACW shareholders he finds one for them in 12 or 18 months when they are much higher.**

**Jason Loveridge ex global head of Life Sciences for JAFCO / Nomura - first investor in Morphysis which is a \$2 bill company**

**CEO Dr Bill Ketelby- ex Pfizer and involved in developing Aricept the current market leader in Alzheimer's treatment**

**George Morstyn - ex Vice president of Development and Chief Medical Officer at Amgen Inc - one of the biggest if not the biggest Bio Tech in the world**

**What do these guys know we don't & why are they on the board of some small little Aussie bio tech..... ????????????**

**Capped at 40mil - with plenty of Arthur Ash in the bank (cash that is)**


***Most would be aware that bio tech stocks are extremely speculative but if they get it right, they can also be life changing. (think CSL, SRX, RHC, to name a few)***

***I'm hoping that they can get it right for all the ACW shareholders & more importantly for all Alzheimer's sufferers around the world as it's a shocking disease as many of you would know.***

***There was also a very good article written on these guys today by the girls and boys at "Stockhead" and I am more than happy to share that with any of you that are interested.***

## **ALZHEIMER'S CARE**

### **THE ALZHEIMER'S TIMELINE**



Nick Kelso

Client Adviser

p: 02 8379 2962

m: 0404 003 613

e: [nk@huntercap.com.au](mailto:nk@huntercap.com.au)

For Hunter Capital Advisors Pty Ltd Disclaimer click [here](#)

For a free subscription to the full report please email Nick Kelso



The idea of this report is to be informative and hopefully point out stocks that you wouldn't ordinarily have seen during the day.

This report IS NOT personal advice.

**It is very important to refer to the ASX website for information on any stocks that are contained in this report and as always please consult your financial adviser before acting .**

This report is written by myself and the views in this report may not accurately reflect the same views as Hunter Capital.

If I have bought stocks or hold them I will let you know about it but it doesn't mean that it is a good buy.

If looking at anything mentioned in this report **please consult your financial adviser before acting.**

This report is written by myself, I don't have the luxury of having a big team to help with this report there will be errors in this report, spelling mistakes, grammar mistakes, closing prices etc etc.

Please check all the facts yourself and don't take what I have written quickly between 4pm & 6pm as gospel.

If you are a broker or even investor that is receiving this report more than happy to get ideas and feedback on stocks that you think I should be looking at or writing about.

**I will not tolerate any keyboard warriors.**

' The trend is your friend ..... until the bend at the end'

If you don't like what I write or my writing style please just email me unsubscribe and you will be taken off the list.

I also have a stockbroking business to run during the day so anyone that does send me queries or ideas I will try and get back to you as soon as possible.

**If you would like to be offered stock in the wide variety of placements and IPOs that I am showed please let me know and I will add you to my list so you have a chance to bid for the stock when it becomes available.**

**708 or sophisticated investors happy to show placements.**

**Non 708 investors happy to show any deals that are available for you to participate in.**

My company and I may receive fees from some companies mentioned in this report.

If you are receiving this from someone else please just send me an email directly and would be happy to add you to my distribution list.

And to finish off one of the world's longest disclaimers

Go Hard